MedTrace Logo

Efficacy And Safety Study Of Naftopidil to Patients Treatment With LUTS

NCT01203371 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2023-02-08

No results posted yet for this study

Summary

The purpose of this study is to evaluate the effectiveness and safety of Naftopidil and Tamsulosin in the treatment of lower urinary tract symptoms through a comparative study of patients with benign prostatic hyperplasia.

Conditions

  • Hyperplasia

Interventions

DRUG

Naftopidil

0,25 mg (2weeks) and 0,50 mg (10 weeks)

DRUG

Tamsulosin

0,4 mg/day

Sponsors & Collaborators

  • Apsen Farmaceutica S.A.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
90 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-01
Primary Completion
2011-09-01
Completion
2012-01-01

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01203371 on ClinicalTrials.gov